Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Press

Showing results (151-160 of 273) with videos related to

Pageof 28
Sort By:
NPJ Breast Cancer|October 9, 2021
A careful reassessment of anthracycline use in curable breast cancerSara Alsterlind Hurvitz, Nicholas P McAndrew, Aditya Bardia, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|April 6, 2022
A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy AloneMonika D Polewski, Gitte B Nielsen, Ying Gu, et al.
Oncogene|October 5, 1995
Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study GroupW J Levin, M F Press, R B Gaynor, et al.
The American Journal of Pathology|July 4, 2006
Receptor tyrosine kinase EphB4 is a survival factor in breast cancerS Ram Kumar, Jasbir Singh, Guangbin Xia, et al.
Clinical Breast Cancer|March 7, 2020
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast CancerReshma Mahtani, Frankie-Ann Holmes, Sunil Badve, et al.
BMC Cancer|December 15, 2012
Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosisNuran Bektas Serce, Andreas Boesl, Irina Klaman, et al.
Breast Cancer Research and Treatment|April 1, 2014
HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristicsPeter A Fasching, Sebastian Weihbrecht, Lothar Haeberle, et al.
BMC Cancer|February 3, 2009
Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic CohortChristopher A Haiman, Rachel R Garcia, Chris Hsu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerDavid B Agus, Michael S Gordon, Charles Taylor, et al.
Clinical Breast Cancer|February 5, 2020
Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG)Muaiad Kittaneh, Sunil Badve, Humberto Caldera, et al.
Pageof 28

Showing results (151-160 of 273) with videos related to

Sort By:
Pageof 28
NPJ Breast Cancer|October 9, 2021
A careful reassessment of anthracycline use in curable breast cancerSara Alsterlind Hurvitz, Nicholas P McAndrew, Aditya Bardia, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|April 6, 2022
A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy AloneMonika D Polewski, Gitte B Nielsen, Ying Gu, et al.
Oncogene|October 5, 1995
Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study GroupW J Levin, M F Press, R B Gaynor, et al.
The American Journal of Pathology|July 4, 2006
Receptor tyrosine kinase EphB4 is a survival factor in breast cancerS Ram Kumar, Jasbir Singh, Guangbin Xia, et al.
Clinical Breast Cancer|March 7, 2020
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast CancerReshma Mahtani, Frankie-Ann Holmes, Sunil Badve, et al.
BMC Cancer|December 15, 2012
Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosisNuran Bektas Serce, Andreas Boesl, Irina Klaman, et al.
Breast Cancer Research and Treatment|April 1, 2014
HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristicsPeter A Fasching, Sebastian Weihbrecht, Lothar Haeberle, et al.
BMC Cancer|February 3, 2009
Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic CohortChristopher A Haiman, Rachel R Garcia, Chris Hsu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerDavid B Agus, Michael S Gordon, Charles Taylor, et al.
Clinical Breast Cancer|February 5, 2020
Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG)Muaiad Kittaneh, Sunil Badve, Humberto Caldera, et al.
Pageof 28